Aerovate Therapeutics, Inc.
AVTE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 50% |
| R&D Expenses | $22 | $23 | $0 | $2 |
| G&A Expenses | $5 | $5 | $3 | $5 |
| SG&A Expenses | $5 | $5 | $3 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $27 | $28 | $3 | $6 |
| Operating Income | -$27 | -$28 | -$3 | -$6 |
| % Margin | – | – | – | -5,717% |
| Other Income/Exp. Net | $2 | -$4 | $1 | $1 |
| Pre-Tax Income | -$25 | -$32 | -$3 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$25 | -$32 | -$3 | -$5 |
| % Margin | – | – | – | -4,848.2% |
| EPS | -482.25 | -863.46 | -0.09 | -0.19 |
| % Growth | 44.1% | -959,300% | 52.6% | – |
| EPS Diluted | -482.25 | -863.46 | -0.09 | -0.19 |
| Weighted Avg Shares Out | 40 | 28 | 29 | 29 |
| Weighted Avg Shares Out Dil | 40 | 28 | 29 | 29 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$25 | -$28 | -$3 | -$6 |
| % Margin | – | – | – | -5,709.8% |